StockData
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. (AIM) stock

AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$0.14−0.01 (-3.36%)

Close on Nov 13, 2026Market cap $4.37MP/E –Yield –

AIM ImmunoTech price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

AIM ImmunoTech's price to sales ratio was 45.3× on Nov 11, 2026, against 37.5× a year earlier. Over the last 5 years it ranged from 13.3× to 376.5×, with a median of 97.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202645.3×+17.4
2025Dec 31, 202527.9×−33.2
2024Dec 31, 202461.1×−91.0
2023Dec 29, 2023152.1×+40.9
2022Dec 30, 2022111.2×−237.8
2021Dec 31, 2021349.0×−76.4
2020Dec 31, 2020425.5×+398.3
2019Apr 30, 201927.2×−21.8
2018Dec 31, 201849.0×+22.0
2017Dec 29, 201727.0×−134.3
2016Dec 30, 2016161.3×+25.6
2015Dec 31, 2015135.7×−115.3
2014Dec 31, 2014250.9×−19.9
2013Dec 31, 2013270.9×+84.6
2012Dec 31, 2012186.3×+5.6
2011Dec 30, 2011180.7×–

More AIM ImmunoTech figures

See a number that looks wrong?